Inflammatory response during ischaemic processes: Adhesion molecules and immunomodulation;Respuesta inflamatoria durante los procesos de isquemia: Moléculas de adhesión e inmunomodulación

Revista de Neurologia

Volumn 51, Issue 1, 2010, Pages 30-40

  Cuenca López, María D ^c   Brea, David ^a   Galindo, María F ^d   Antón Martínez, David ^c,d   Sanz, María J ^b   Agulla, Jesús ^a   Castillo, José ^a   Jordán, Joaquín ^c,e,f  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

^c Universidad de Castilla La Mancha   (Spain)

^d Universitario of Albacete   (Spain)

^e University of Castilla La Mancha   (Spain)

^f Universidad Castilla La Mancha   (Spain)

Author keywords

Adhesion molecules; Cerebral ischaemia; Immunomodulation; Inflammatory response; Preconditioning

Indexed keywords

CELL ADHESION MOLECULE; CHEMOKINE; CYTOKINE; IMMUNOGLOBULIN; INTEGRIN;

APOPTOSIS; ASTROCYTE; BLOOD BRAIN BARRIER; BRAIN ISCHEMIA; CELL ACTIVATION; CELL DEATH; CELL INFILTRATION; CYTOKINE PRODUCTION; GENE OVEREXPRESSION; HUMAN; IMMUNITY; IMMUNOMODULATION; IMMUNOSTIMULATION; INFECTION; INFLAMMATION; MICROGLIA; REVIEW; STROKE;

EID: 77954404460     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.5101.2009667     Document Type: Review

References (77)

1. Rutella S, Pierelli L, Bonanno G, Sica S, Ameglio F, Capoluongo E, et al. Role for granulocyte colony-stimulating factor in the generation of human T regulatory type 1 cells. Blood 2002; 100: 2562-71.
2. Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol 2007; 7: 678-89.
3. McEver RP, Cummings RD. Perspectives series: cell adhesion in vascular biology. Role of PSGL-1 binding to selectins in leukocyte recruitment. J Clin Invest 1997; 100: 485-91.
4. Connolly ES Jr, Winfree CJ, Springer TA, Naka Y, Liao H, Yan SD, et al. Cerebral protection in homozygous null ICAM-1 mice after middle cerebral artery occlusion. Role of neutrophil adhesion in the pathogenesis of stroke. J Clin Invest 1996; 97: 209-16. (Pubitemid 26021710)
5. Moore KL, Eaton SF, Lyons DE, Lichenstein HS, Cummings RD, McEver RP. The P-selectin glycoprotein ligand from human neutrophils displays sialylated, fucosylated, O-linked poly-N-acetyllactosamine. J Biol Chem 1994; 269: 23318-27.
6. Huang J, Kim LJ, Mealey R, Marsh HC Jr, Zhang Y, Tenner AJ, et al. Neuronal protection in stroke by an sLex-glycosylated complement inhibitory protein. Science 1999; 285: 595-9. (Pubitemid 129515299)
7. Rivera-Nieves J, Burcin TL, Olson TS, Morris MA, McDuffie M, Cominelli F, et al. Critical role of endothelial P-selectin glycoprotein ligand 1 in chronic murine ileitis. J Exp Med 2006; 203: 907-17.
8. Da Costa Martins P, García-Vallejo JJ, Van Thienen JV, Fernández-Borja M, Van Gils JM, Beckers C, et al. P-selectin glycoprotein ligand-1 is expressed on endothelial cells and mediates monocyte adhesion to activated endothelium. Arterioscler Thromb Vasc Biol 2007; 27: 1023-9.
9. Stenberg PE, Shuman MA, Levine SP, Bainton DF. Redistribution of alpha-granules and their contents in thrombin-stimulated platelets. J Cell Biol 1984; 98: 748-60.
10. Diacovo TG, Roth SJ, Buccola JM, Bainton DF, Springer TA. Neutrophil rolling, arrest, and transmigration across activated, surface-adherent platelets via sequential action of P-selectin and the beta 2-integrin CD11b/CD18. Blood 1996; 88: 146-57.
11. Cha JK, Jeong MH, Kim EK, Lim YJ, Ha BR, Kim SH, et al. Surface expression of P-selectin on platelets is related with clinical worsening in acute ischemic stroke. J Korean Med Sci 2002; 17: 811-6.
12. Zhang RL, Chopp M, Zhang ZG, Phillips ML, Rosenbloom CL, Cruz R, et al. E-selectin in focal cerebral ischemia and reperfusion in the rat. J Cereb Blood Flow Metab 1996; 16: 1126-36. (Pubitemid 26365363)
13. Zhang R, Chopp M, Zhang Z, Jiang N, Powers C. The expression of P- and E-selectins in three models of middle cerebral artery occlusion. Brain Res 1998; 785: 207-14.
14. Mayadas TN, Johnson RC, Rayburn H, Hynes RO, Wagner DD. Leukocyte rolling and extravasation are severely compromised in P selectin-deficient mice. Cell 1993; 74: 541-54.
15. Huang J, Choudhri TF, Winfree CJ, McTaggart RA, Kiss S, Mocco J, et al. Postischemic cerebrovascular E-selectin expression mediates tissue injury in murine stroke. Stroke 2000; 31: 3047-53.
16. Mocco J, Choudhri T, Huang J, Harfeldt E, Efros L, Klingbeil C, et al. HuEP5C7 as a humanized monoclonal anti-E/P-selectin neurovascular protective strategy in a blinded placebo-controlled trial of nonhuman primate stroke. Circ Res 2002; 91: 907-14.
17. Lehmberg J, Beck J, Baethmann A, Uhl E. Effect of P-selectin inhibition on leukocyte-endothelium interaction and survival after global cerebral ischemia. J Neurol 2006; 253: 357-63.
18. Chen Y, Ruetzler C, Pandipati S, Spatz M, McCarron RM, Becker K, et al. Mucosal tolerance to E-selectin provides cell-mediated protection against ischemic brain injury. Proc Natl Acad Sci U S A 2003; 100: 15107-12.
19. Yenari MA, Sun GH, Kunis DM, Onley D, Vexler V. L-selectin inhibition does not reduce injury in a rabbit model of transient focal cerebral ischemia. Neurol Res 2001; 23: 72-8.
20. Springer TA. Adhesion receptors of the immune system. Nature 1990; 346: 425-34.
21. Frijns CJ, Kappelle LJ. Inflammatory cell adhesion molecules in ischemic cerebrovascular disease. Stroke 2002; 33: 2115-22.
22. Zhang RL, Chopp M, Chen H, Garcia JH. Temporal profile of ischemic tissue damage, neutrophil response, and vascular plugging following permanent and transient (2H) middle cerebral artery occlusion in the rat. J Neurol Sci 1994; 125: 3-10.
23. Hess DC, Zhao W, Carroll J, McEachin M, Buchanan K. Increased expression of ICAM-1 during reoxygenation in brain endothelial cells. Stroke 1994; 25: 1463-8. (Pubitemid 24198596)
24. Stanimirovic D, Shapiro A, Wong J, Hutchison J, Durkin J. The induction of ICAM-1 in human cerebromicrovascular endothelial cells (HCEC) by ischemia-like conditions promotes enhanced neutrophil/HCEC adhesion. J Neuroimmunol 1997; 76: 193-205.
25. Shyu KG, Chang H, Lin CC. Serum levels of intercellular adhesion molecule-1 and E-selectin in patients with acute ischaemic stroke. J Neurol 1997; 244: 90-3.
26. Bitsch A, Klene W, Murtada L, Prange H, Rieckmann P. A longitudinal prospective study of soluble adhesion molecules in acute stroke. Stroke 1998; 29: 2129-35.
27. Lindsberg PJ, Carpen O, Paetau A, Karjalainen-Lindsberg ML, Kaste M. Endothelial ICAM-1 expression associated with inflammatory cell response in human ischemic stroke. Circulation 1996; 94: 939-45. (Pubitemid 26292844)
28. Endres M, Laufs U, Merz H, Kaps M. Focal expression of intercellular adhesion molecule-1 in the human carotid bifurcation. Stroke 1997; 28: 77-82. (Pubitemid 27039469)
29. DeGraba TJ, Siren AL, Penix L, McCarron RM, Hargraves R, Sood S, et al. Increased endothelial expression of intercellular adhesion molecule-1 in symptomatic versus asymptomatic human carotid atherosclerotic plaque. Stroke 1998; 29: 1405-10.
30. Hwang SJ, Ballantyne CM, Sharrett AR, Smith LC, Davis CE, Gotto AM Jr, et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation 1997; 96: 4219-25.
31. Vemuganti R, Dempsey RJ, Bowen KK. Inhibition of intercellular adhesion molecule-1 protein expression by antisense oligonucleotides is neuroprotective after transient middle cerebral artery occlusion in rat. Stroke 2004; 35: 179-84.
32. Zhang RL, Chopp M, Li Y, Zaloga C, Jiang N, Jones ML, et al. Anti-ICAM-1 antibody reduces ischemic cell damage after transient middle cerebral artery occlusion in the rat. Neurology 1994; 44: 1747-51.
33. Bowes MP, Zivin JA, Rothlein R. Monoclonal antibody to the ICAM-1 adhesion site reduces neurological damage in a rabbit cerebral embolism stroke model. Exp Neurol 1993; 119: 215-9. (Pubitemid 23132018)
34. Zhang LH, Wei EQ. Neuroprotective effect of ONO-1078, a leukotriene receptor antagonist, on transient global cerebral ischemia in rats. Acta Pharmacol Sin 2003; 24: 1241-7.
35. Justicia C, Martín A, Rojas S, Gironella M, Cervera A, Panes J, et al. Anti-VCAM-1 antibodies did not protect against ischemic damage either in rats or in mice. J Cereb Blood Flow Metab 2006; 26: 421-32.
36. Haring HP, Akamine BS, Habermann R, Koziol JA, Del Zoppo GJ. Distribution of integrin-like immunoreactivity on primate brain microvasculature. J Neuropathol Exp Neurol 1996; 55: 236-45. (Pubitemid 26069301)
37. Harmon D, Lan W, Shorten G. The effect of aprotinin on hypoxia-reoxygenation-induced changes in neutrophil and endothelial function. Eur J Anaesthesiol 2004; 21: 973-9.
38. Zhang ZG, Chopp M, Tang WX, Jiang N, Zhang RL. Postischemic treatment (2-4 h) with anti-CD11b and anti-CD18 monoclonal antibodies are neuroprotective after transient (2 h) focal cerebral ischemia in the rat. Brain Res 1995; 698: 79-85.
39. Prestigiacomo CJ, Kim SC, Connolly ES Jr, Liao H, Yan SF, Pinsky DJ. CD18-mediated neutrophil recruitment contributes to the pathogenesis of reperfused but not nonreperfused stroke. Stroke 1999; 30: 1110-7.
40. Krams M, Lees KR, Hacke W, Grieve AP, Orgogozo JM, Ford GA. Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN): an adaptive dose-response study of UK-279,276 in acute ischemic stroke. Stroke 2003; 34: 2543-8.
41. Becker K, Kindrick D, Relton J, Harlan J, Winn R. Antibody to the alpha4 integrin decreases infarct size in transient focal cerebral ischemia in rats. Stroke 2001; 32: 206-11. (Pubitemid 32063847)
42. Takeda K, Akira S. Toll-like receptors in innate immunity. Int Immunol 2005; 17: 1-14.
43. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004; 5: 987-95.
44. Akira S, Sato S. Toll-like receptors and their signaling mechanisms. Scand J Infect Dis 2003; 35: 555-62.
45. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001; 2: 675-80.
46. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol 2001; 1: 135-45.
47. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003; 21: 335-76.
48. Ziegler G, Harhausen D, Schepers C, Hoffmann O, Rohr C, Prinz V, et al. TLR2 has a detrimental role in mouse transient focal cerebral ischemia. Biochem Biophys Res Commun 2007; 359: 574-9.
49. Nguyen KB, Watford WT, Salomon R, Hofmann SR, Pien GC, Morinobu A, et al. Critical role for STAT4 activation by type 1 interferons in the interferon-gamma response to viral infection. Science 2002; 297: 2063-6.
50. Cao CX, Yang QW, Lv FL, Cui J, Fu HB, Wang JZ. Reduced cerebral ischemia-reperfusion injury in Toll-like receptor 4 deficient mice. Biochem Biophys Res Commun 2007; 353: 509-14.
51. Caso JR, Pradillo JM, Hurtado O, Lorenzo P, Moro MA, Lizasoain I. Toll-like receptor 4 is involved in brain damage and inflammation after experimental stroke. Circulation 2007; 115: 1599-608.
52. Caso JR, Pradillo JM, Hurtado O, Leza JC, Moro MA, Lizasoain I. Toll-like receptor 4 is involved in subacute stress-induced neuroinflammation and in the worsening of experimental stroke. Stroke 2008; 39: 1314-20.
53. Zhang Z, Schluesener HJ. Mammalian toll-like receptors: from endogenous ligands to tissue regeneration. Cell Mol Life Sci 2006; 63: 2901-7.
54. Prass K, Meisel C, Hoflich C, Braun J, Halle E, Wolf T, et al. Stroke-induced immunodeficiency promotes spontaneous bacterial infections and is mediated by sympathetic activation reversal by poststroke T helper cell type 1-like immunostimulation. J Exp Med 2003; 198: 725-36.
55. Hendrix S, Nitsch R. The role of T helper cells in neuroprotection and regeneration. J Neuroimmunol 2007; 184: 100-12. (Pubitemid 46365994)
56. Dirnagl U, Klehmet J, Braun JS, Harms H, Meisel C, Ziemssen T, et al. Stroke-induced immunodepression: experimental evidence and clinical relevance. Stroke 2007; 38: 770-3.
57. Chamorro A, Urra X, Planas AM. Infection after acute ischemic stroke: a manifestation of brain-induced immunodepression. Stroke 2007; 38: 1097-103.
58. Palinski W. Immunomodulation: a new role for statins? Nat Med 2000; 6: 1311-2.
59. Zvara DA, Colonna DM, Deal DD, Vernon JC, Gowda M, Lundell JC. Ischemic preconditioning reduces neurologic injury in a rat model of spinal cord ischemia. Ann Thorac Surg 1999; 68: 874-80.
60. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986; 74: 1124-36.
61. Tsuyama H, Shimizu K, Yoshimoto K, Nezuka H, Ito H, Yamamoto S, et al. Protective effect of ischemic preconditioning on hepatic ischemia-reperfusion injury in mice. Transplant Proc 2000; 32: 2310-3.
62. Toosy N, McMorris EL, Grace PA, Mathie RT. Ischaemic preconditioning protects the rat kidney from reperfusion injury. BJU Int 1999; 84: 489-94.
63. Kitagawa K, Matsumoto M, Tagaya M, Hata R, Ueda H, Niinobe M, et al. 'Ischemic tolerance' phenomenon found in the brain. Brain Res 1990; 528: 21-4.
64. Weih M, Kallenberg K, Bergk A, Dirnagl U, Harms L, Wernecke KD, et al. Attenuated stroke severity after prodromal TIA: a role for ischemic tolerance in the brain? Stroke 1999; 30: 1851-4.
65. Dirnagl U, Simon RP, Hallenbeck JM. Ischemic tolerance and endogenous neuroprotection. Trends Neurosci 2003; 26: 248-54.
66. Blondeau N, Widmann C, Lazdunski M, Heurteaux C. Activation of the nuclear factor-kappaB is a key event in brain tolerance. J Neurosci 2001; 21: 4668-77. (Pubitemid 32565625)
67. Mattson MP, Culmsee C, Yu Z, Camandola S. Roles of nuclear factor kappaB in neuronal survival and plasticity. J Neurochem 2000; 74: 443-56.
68. Cuenca-López MD, Brea D, Segura T, Galindo MF, Antón-Martínez D, Agulla J, et al. La inflamación como agente terapéutico en el infarto cerebral: respuesta inflamatoria celular y mediadores inflamatorios. Rev Neurol 2010; 50: 349-59.
69. Tasaki K, Ruetzler CA, Ohtsuki T, Martin D, Nawashiro H, Hallenbeck JM. Lipopolysaccharide pre-treatment induces resistance against subsequent focal cerebral ischemic damage in spontaneously hypertensive rats. Brain Res 1997; 748: 267-70.
70. Karikó K, Weissman D, Welsh FA. Inhibition of toll-like receptor and cytokine signaling - a unifying theme in ischemic tolerance. J Cereb Blood Flow Metab 2004; 24: 1288-304.
71. Becker KJ, McCarron RM, Ruetzler C, Laban O, Sternberg E, Flanders KC, et al. Immunologic tolerance to myelin basic protein decreases stroke size after transient focal cerebral ischemia. Proc Natl Acad Sci U S A 1997; 94: 10873-8.
72. Bruce AJ, Boling W, Kindy MS, Peschon J, Kraemer PJ, Carpenter MK, et al. Altered neuronal and microglial responses to excitotoxic and ischemic brain injury in mice lacking TNF receptors. Nat Med 1996; 2: 788-94.
73. Nawashiro H, Tasaki K, Ruetzler CA, Hallenbeck JM. TNF-alpha pretreatment induces protective effects against focal cerebral ischemia in mice. J Cereb Blood Flow Metab 1997; 17: 483-90. (Pubitemid 27250974)
74. Jordán J, Segura T, Brea D, Galindo MF, Castillo J. Inflammation as therapeutic objective in stroke. Curr Pharm Des 2008; 14: 3549-64.
75. Segura T, Calleja S, Jordán J. Recommendations and treatment strategies for the management of acute ischemic stroke. Expert Opin Pharmacother 2008; 9: 1071-85.
76. Jordán J, Ikuta I, García-García J, Calleja S, Segura T. Stroke pathophysiology: management challenges and new treatment advances. J Physiol Biochem 2007; 63: 261-77.
77. Fernández-Gómez FJ, Hernández F, Argandoña L, Galindo MF, Segura T, Jordán J. Farmacología de la neuroprotección en el ictus isquémico agudo. Rev Neurol 2008; 47: 253-60.